Sagimet Biosciences Inc. (SGMT) stock
SGMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.85−0.28 (-2.76%)
Close on Nov 17, 2026Market cap $612.26MP/E –Yield –
Sagimet Biosciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Sagimet Biosciences's operating income for the twelve months ending Jun 30, 2026 was -$52.63M. For fiscal 2025 it was -$56.89M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$56.89M | – |
| FY2024 | Dec 31, 2024 | -$54.45M | – |
| FY2023 | Dec 31, 2023 | -$30.74M | – |
| FY2022 | Dec 31, 2022 | -$31.06M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$15.82M | – |
| Q1 FY2026 | Mar 31, 2026 | -$11.71M | – |
| Q4 FY2025 | Dec 31, 2025 | -$10.77M | – |
| Q3 FY2025 | Sep 30, 2025 | -$14.33M | – |
| Q2 FY2025 | Jun 30, 2025 | -$11.93M | – |
| Q1 FY2025 | Mar 31, 2025 | -$19.87M | – |
| Q4 FY2024 | Dec 31, 2024 | -$18.20M | – |
| Q3 FY2024 | Sep 30, 2024 | -$16.90M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.59M | – |
| Q1 FY2024 | Mar 31, 2024 | -$8.77M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.47M | – |
| Q3 FY2023 | Sep 30, 2023 | -$7.45M | – |
| Q2 FY2023 | Jun 30, 2023 | -$7.06M | – |
| Q1 FY2023 | Mar 31, 2023 | -$6.77M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.39M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.69M | – |
| Q2 FY2022 | Jun 30, 2022 | -$7.24M | – |
See a number that looks wrong?